Developments in China’s biotechnology sector, from research breakthroughs and diagnostics to industrial biotech and manufacturing.
The influx signals a strategic pivot, as Beijing funnels its most promising private innovators—particularly in biotech and AI—toward Hong Kong’s deep capital markets, reshaping the…
A Chinese diagnostic firm’s plan to expand in Hong Kong signals how pandemic-era public health partnerships can become a launchpad for long-term commercial strategy in…
For global pharmaceutical professionals, the prospect of a Chinese company successfully navigating US biological drug approval for the first time signals a shift in competitive…
A profitable Hong Kong-based biotechnology company is moving toward a public listing to finance the development of treatments for Alzheimer’s and other neurological diseases, a…
For global biotech and life sciences firms weighing an IPO in Asia, Hong Kong’s willingness to rewrite its listing rules signals a serious effort to…
As the global race for a Covid-19 cure accelerates, China’s biotechnology sector is experiencing a powerful wave of consolidation and capital inflows, signalling a strategic…
For global pharmaceutical and tech investors, the convergence of deep-pocketed AI giants and drug discovery marks a pivotal shift in how new therapies may be…
For global pharmaceutical executives and investors, the coming wave of consolidation in China’s outsourced drug discovery sector signals an urgent window for strategic positioning in…
For global pharmaceutical executives and investors tracking China’s ascent in innovative drug development, the scale of Chi-Med’s planned commercial buildout signals confidence not just in…
For global professionals tracking China’s biotech trajectory, the Hong Kong-Singapore comparison is a revealing lens on how policy, infrastructure, and regional integration shape a sector’s…
No products in the cart.
